EJC Skin Cancer
ISSN 2772-6118 · Elsevier BV · Netherlands · active 2023–2026
Metrics
- Scimago quartile (2025)
- Q3
- Cites per paper (2y)
- 0.2
- SJR
- 0.4
- h-index
- 6
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 5 October 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, EJC Skin Cancer is Q3 in all 2 of its subject categories.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Dermatology | Q3 | #85 of 153 |
| Oncology | Q3 | #296 of 426 |
- Cites per document (2 years, Scopus)
- 1.14
- Documents indexed in 2025 (Scopus)
- 49
OpenAlex counts about 0.2 citations per paper over two years; Scopus, through Scimago, counts 1.14 per document. The two databases index different journals, documents and citations, so the figures differ. Neither is a Clarivate Journal Impact Factor.
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Responding time
- Submission to publication
- ~12 wkDOAJ self-reported
Turnaround figures are indicative, not a guarantee: DOAJ values are self-reported by the journal (average weeks, submission to publication); library estimates are medians of the received/accepted dates printed in papers we hold. Editorial times vary by article type and season — confirm on the journal’s own site.
Indexing & access
- Indexed in
- DOAJScopusWeb of SciencePubMed
- Access status:
- gold. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
- Article processing charge
- Article processing charge (APC): $1,170 per accepted article (DOAJ). Fee waivers are available.
Scope
Frequently asked
Is EJC Skin Cancer a predatory journal?
Our screening does not flag EJC Skin Cancer. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.
Is EJC Skin Cancer indexed in Scopus or Web of Science?
Per our venue index, EJC Skin Cancer appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of EJC Skin Cancer?
Papers in EJC Skin Cancer are cited about 0.2 times each within two years of publication, and Scimago places it in Q3, with an h-index of 6. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is EJC Skin Cancer (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, EJC Skin Cancer is Q3 in all 2 of its subject categories. By category: Dermatology: Q3, #85 of 153; Oncology: Q3, #296 of 426. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; EJC Skin Cancer is cited about 0.2 times per paper over two years, with an h-index of 6.
What is the Web of Science (JCR) quartile of EJC Skin Cancer?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for EJC Skin Cancer. The open equivalent is its Scimago quartile, Q3, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is EJC Skin Cancer open access?
Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
What is the article processing charge (APC) to publish in EJC Skin Cancer?
Article processing charge (APC): $1,170 per accepted article (DOAJ). Fee waivers are available. The exact charge can vary by article type and any fee waiver, so confirm the current amount on the journal's own site.
How long does EJC Skin Cancer take to publish a paper?
Submission to publication for EJC Skin Cancer takes about ~12 wk — DOAJ self-reported. Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for EJC Skin Cancer.
Ready to submit? Tools for your next paper
Similar venues
- Journal of Oncology Pharmacy PracticeQ3 · SAGE Publishing
- Asia-Pacific Journal of Clinical OncologyQ2 · Wiley
- Case Reports in OncologyQ3 · Karger Publishers
- Nowotwory Journal of OncologyQ3 · Via Medica
- Immuno-Oncology TechnologyQ1 · Elsevier BV
- Indian Journal of Medical and Paediatric OncologyQ3 · Thieme Medical Publishers (Germany)
Compare it with its peers: Ranked Oncology journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.